VanEck Pharmaceutical ETF $PPH Shares Sold by Level Four Advisory Services LLC

Level Four Advisory Services LLC cut its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 59.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,031 shares of the company’s stock after selling 22,464 shares during the quarter. Level Four Advisory Services LLC owned 0.12% of VanEck Pharmaceutical ETF worth $1,358,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Citigroup Inc. increased its position in shares of VanEck Pharmaceutical ETF by 987.8% in the third quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock valued at $64,896,000 after buying an additional 652,175 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new stake in VanEck Pharmaceutical ETF in the 2nd quarter valued at about $28,587,000. JPMorgan Chase & Co. increased its holdings in VanEck Pharmaceutical ETF by 2,852.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock valued at $22,503,000 after acquiring an additional 247,171 shares in the last quarter. Verity & Verity LLC purchased a new position in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $11,551,000. Finally, Tower Research Capital LLC TRC raised its position in VanEck Pharmaceutical ETF by 346,140.0% during the second quarter. Tower Research Capital LLC TRC now owns 34,624 shares of the company’s stock worth $3,046,000 after acquiring an additional 34,614 shares during the last quarter.

VanEck Pharmaceutical ETF Price Performance

Shares of NASDAQ PPH opened at $106.33 on Friday. The firm’s 50-day moving average is $107.42 and its two-hundred day moving average is $98.78. The company has a market capitalization of $1.17 billion, a PE ratio of 20.21 and a beta of 0.54. VanEck Pharmaceutical ETF has a 12-month low of $77.67 and a 12-month high of $112.58.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 29th were issued a dividend of $0.3106 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Monday, December 29th.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.